4-chlorophenylisobutylamine
4-Chlorophenylisobutylamine, also known as 4-CAB or by its chemical name 1-(4-chlorophenyl)isobutylamine, is a chemical compound that belongs to the class of organic compounds known as phenethylamines. Phenethylamines are a broad family of compounds that have a core structure consisting of a phenyl ring attached to an ethane-1,2-diamine. 4-CAB is closely related to other psychoactive compounds and has been studied for its potential effects and interactions within biological systems, particularly in the context of neuroscience and pharmacology.
Chemistry[edit | edit source]
4-Chlorophenylisobutylamine is characterized by the presence of a chlorine atom attached to the fourth position of the phenyl ring, a structural feature that significantly influences its chemical and pharmacological properties. The isobutylamine chain attached to the phenyl ring classifies it as an isobutylamine, distinguishing it from other phenethylamines with different alkylamine chains.
Pharmacology[edit | edit source]
The pharmacological profile of 4-CAB is not well-documented, but it is understood to interact with various neurotransmitter systems in the brain, potentially including those involving dopamine, serotonin, and norepinephrine. These interactions could theoretically underpin a range of effects, from psychoactive to sympathomimetic outcomes, depending on the compound's affinity and efficacy at different receptor sites. However, the specific actions of 4-CAB on these neurotransmitter systems and its overall effects on human physiology and behavior remain largely speculative due to the limited research available.
Potential Uses and Research[edit | edit source]
Research into 4-Chlorophenylisobutylamine has been sparse, and it has not found widespread application in any medical or therapeutic context. Its structural similarity to other phenethylamines suggests potential for research into neurological and psychiatric conditions, possibly as a tool to understand receptor dynamics or as a lead compound for the development of new therapeutics. Nonetheless, the lack of comprehensive studies means that any potential uses are purely hypothetical at this stage.
Legal Status[edit | edit source]
The legal status of 4-CAB varies by country, but it may be regulated under laws pertaining to phenethylamines or psychoactive substances in general. Given its potential for psychoactive effects, it could be subject to controls aimed at preventing non-medical use. However, specific information on its legal classification in different jurisdictions is not readily available and would depend on national or regional drug control policies.
Safety and Toxicology[edit | edit source]
There is limited information on the safety, toxicity, and potential health risks associated with 4-Chlorophenylisobutylamine. As with many research chemicals, the absence of detailed toxicological data means that the safety profile of 4-CAB is not well-understood. Caution is advised for any use outside of controlled research settings, and the compound should be handled with standard laboratory safety practices in mind.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD